Patents by Inventor Romain LEGRAND
Romain LEGRAND has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11389489Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.Type: GrantFiled: June 8, 2020Date of Patent: July 19, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Naouel Tennoune, Romain Legrand
-
Patent number: 11369645Abstract: The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.Type: GrantFiled: June 16, 2020Date of Patent: June 28, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Nicolas Lucas, Romain Legrand
-
Patent number: 11319352Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.Type: GrantFiled: April 3, 2018Date of Patent: May 3, 2022Assignees: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUENInventors: Serguei Fetissov, Grégory Lambert, Romain Legrand, Nicolas Lucas
-
Publication number: 20210401020Abstract: A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10?4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.Type: ApplicationFiled: November 28, 2019Publication date: December 30, 2021Applicants: TARGEDYS, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUENInventors: Clémentine PICOLO, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS
-
Publication number: 20210107952Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.Type: ApplicationFiled: April 3, 2018Publication date: April 15, 2021Applicants: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUENInventors: Serguei FETISSOV, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS
-
Publication number: 20210008125Abstract: The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.Type: ApplicationFiled: June 16, 2020Publication date: January 14, 2021Inventors: Serguei Fetissov, Emmanuelle De, Naouel Tennoune, Jonathan Breton, Philippe Chan-Tchi-Song, Pierre Dechelotte, Romain Legrand, Gregory Lambert
-
Patent number: 10888592Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of Hafnia alvei.Type: GrantFiled: April 5, 2017Date of Patent: January 12, 2021Assignees: TARGEDYS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Romain Legrand, Nicolas Lucas
-
Publication number: 20200297783Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.Type: ApplicationFiled: June 8, 2020Publication date: September 24, 2020Inventors: Serguei FETISSOV, Pierre DECHELOTTE, Jonathan BRETON, Gregory LAMBERT, Naouel TENNOUNE, Romain LEGRAND
-
Patent number: 10729770Abstract: The present invention relates to ClpB expressing bacteria and their impact on obesity. The present invention relates to bacterial ClpB protein and ClpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one ClpB expressing bacterium as well as probiotics not expressing ClpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.Type: GrantFiled: July 11, 2018Date of Patent: August 4, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Emmanuelle De, Naouel Tennoune, Jonathan Breton, Philippe Chan-Tchi-Song, Pierre Dechelotte, Romain Legrand, Gregory Lambert
-
Patent number: 10682389Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.Type: GrantFiled: April 5, 2016Date of Patent: June 16, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITÉ´DE ROUEN, TARGEDYSInventors: Sergueï Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Romain Legrand
-
Publication number: 20200131495Abstract: Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and/or prevention of inflammation, in particular overweight and/or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.Type: ApplicationFiled: April 3, 2018Publication date: April 30, 2020Applicants: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUENInventors: Serguei FETISSOV, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS, Manon DOMINIQUE
-
Publication number: 20180369378Abstract: The present invention relates to CIpB expressing bacteria and their impact on obesity. The present invention relates to bacterial CIpB protein and CIpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one CIpB expressing bacterium as well as probiotics not expressing CIpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.Type: ApplicationFiled: July 11, 2018Publication date: December 27, 2018Inventors: Serguei Fetissov, Emmanuelle De, Naouel Tennoune, Jonathan Breton, Philippe Chan-Tchi-Song, Pierre Dechelotte, Romain Legrand, Gregory Lambert
-
Publication number: 20160313348Abstract: The present invention relates to bacterial Clp B protein and Clp B expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one Clp B expressing bacterium as well as probiotics not expressing Clp B protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.Type: ApplicationFiled: December 4, 2014Publication date: October 27, 2016Inventors: Serguei Fetissov, Emmanuelle De, Naouel Tennoune, Jonathan Breton, Philippe Chan-Tchi-Song, Pierre Dechelotte, Romain Legrand
-
Publication number: 20160123989Abstract: The present invention relates to methods and kits of determining whether a subject is susceptible to have a hyper-aggressive behaviour. In particular, the present invention relates to a method for determining whether a subject is susceptible to have a hyper-aggressive behaviour comprising the steps consisting of i) isolating the auto antibodies that bind to adrenocorticotropic hormone (ACTH) from a blood sample obtained from the subject, ii) determining the affinity of the isolated autoantibodies iii) comparing the affinity determined at step ii) with a predetermined reference value and iv) concluding that the subject is susceptible to have a hyper-aggressive behaviour when the affinity determined at step ii) is higher than the predetermined reference value.Type: ApplicationFiled: June 20, 2014Publication date: May 5, 2016Inventors: Serguei FETISSOV, Pierre DECHELOTTE, Henning VÆRØY, Romain LEGRAND
-
Publication number: 20160083467Abstract: The present invention relates to antibodies which bind human ghrelin and their use in methods of treating or preventing reduced appetite. The invention further relates to diagnostic tools for determining whether an individual is likely to respond to a method of treating or preventing reduced appetite.Type: ApplicationFiled: April 16, 2014Publication date: March 24, 2016Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE ROUEN, KAGOSHIMA UNIVERSITY, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUENInventors: Serguei FETISSOV, Romain LEGRAND, Pierre DECHELOTTE, Akio INUI, Akihiro ASAKAWA, Kuniko TAKAGI